Xtent to liquidate
This article was originally published in The Gray Sheet
Executive Summary
Developer of the Custom NX biolimus A9-eluting stent with adjustable lengths and bioabsorbable polymer plans to liquidate its assets and dissolve the company, subject to shareholder approval, Xtent announces May 15. The firm cited "continued challenges" in the capital markets when it eliminated most of its employees and began looking for buyers in January (1"The Gray Sheet" Feb. 2, 2009, In Brief)
You may also be interested in...
Xtent seeks buyer
Developer of the Custom NX biolimus A9-eluting stent with adjustable lengths and bioabsorbable polymer will pursue "strategic alternatives," including the possible sale of some or all of the firm's assets, Xtent says Jan. 23. The Menlo Park, Calif.-based company, which went public in 2007, plans to eliminate 112 of its 121 employees as of March 23. The firm cites "continued challenges" in the capital markets. Data on the stent, which has been evaluated in four human trials, was presented at TCT last October (1"The Gray Sheet" Oct. 20, 2008, p. 15)
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.